Literature DB >> 7881671

Failure of talc pleurodesis is associated with increased pleural fibrinolysis.

F Rodriguez-Panadero1, A Segado, J Martin Juan, R Ayerbe, I Torres Garcia, J Castillo.   

Abstract

Diffuse pleural inflammation and fibrin deposition following the instillation of the sclerosing agent is considered necessary for a successful pleural symphysis. We hypothesized that an impairment in fibrin formation or an increased endopleural fibrinolysis would lead to failure of pleurodesis. To investigate changes in the pleural coagulation/fibrinolysis balance, we studied 75 consecutive patients who underwent thoracoscopy. Fifty-four of these patients with malignant pleural effusions and four with a benign recurrent effusion underwent thoracoscopic talc pleurodesis. Another four patients with malignancy and 13 with benign effusions had no talc poudrage performed and were included as a control group. Serial determinations of thrombin-antithrombin III complex (TAT), plasminogen activator inhibitor (PAI), and D-dimer were made in pleural fluid samples taken at the beginning of thoracoscopy (baseline), immediately after thoracoscopic biopsies had been done (postbiopsy), 3 h after thoracoscopy--either with talc poudrage or without--and 24 and 48 h after the procedure, as well as in cases of recurrence of effusions (farline). Successful pleurodesis was obtained in 42 of 52 patients who could be evaluated (81%), and failure was seen in 10. Strong activation of coagulation and production of PAI was observed in all groups, including the control (no talc) group. Fibrinolytic activity (as expressed by D-dimer levels) showed a clear decline 24 h after talc poudrage in patients with a good outcome of pleurodesis, as oppossed to those with bad results and to the control group, and returned to the baseline by 15 d. We conclude that increased pleural fibrinolytic activity is associated with failure of pleurodesis, despite significant inhibitory activity of PAI in all groups.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7881671     DOI: 10.1164/ajrccm/151.3_Pt_1.785

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

Authors:  Carolyn M Dresler; Jemi Olak; James E Herndon; William G Richards; Ernest Scalzetti; Stewart B Fleishman; Kemp H Kernstine; Todd Demmy; David M Jablons; Leslie Kohman; Thomas M Daniel; George B Haasler; David J Sugarbaker
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

Review 3.  Malignant pleural effusions: appropriate treatment approaches.

Authors:  Yener Aydin; Atila Turkyilmaz; Yavuz Selim Intepe; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2009-12

Review 4.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

Review 5.  Interventional pulmonologist perspective: treatment of malignant pleural effusion.

Authors:  Andrew J Sweatt; Arthur Sung
Journal:  Curr Treat Options Oncol       Date:  2014-12

6.  Lung injury after cigarette smoking is particle related.

Authors:  Rahul G Sangani; Andrew J Ghio
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-03-10

7.  Role of talc modulation on cytokine activation in cancer patients undergoing pleurodesis.

Authors:  Yehuda Schwarz; Alex Star
Journal:  Pulm Med       Date:  2012-03-07

8.  The effect of silver nitrate pleurodesis after a failed thoracoscopic talc poudrage.

Authors:  Cecilia Menna; Claudio Andreetti; Mohsen Ibrahim; Giulio Maurizi; Camilla Poggi; Rocco Barile; Francesco Cassiano; Erino A Rendina
Journal:  Biomed Res Int       Date:  2013-09-01       Impact factor: 3.411

9.  Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.

Authors:  Li-Han Hsu; Pei-Chi Hsu; Tien-Ling Liao; An-Chen Feng; Nei-Min Chu; Shu-Huei Kao
Journal:  BMC Cancer       Date:  2016-07-13       Impact factor: 4.430

10.  Predictors of survival in non-small cell lung cancer patients with pleural effusion undergoing thoracoscopy.

Authors:  Li-Xu Xie; Xing-Guang Wang; Wen-Jie You; Xiao-Bin Ma; Yong-Gang Wang; Ting-Ting Liu; Shu-Juan Jiang
Journal:  Thorac Cancer       Date:  2019-05-15       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.